Article: Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleDistinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes
AuthorsXiao, Y1 2
Xu, A1
Law, LSC1
Chen, C1
Li, H2
Li, X2
Yang, L2
Liu, S
Zhou, Z
Lam, KSL1
Issue Date2012
PublisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
CitationJournal of Clinical Endocrinology and Metabolism, 2012, v. 97 n. 1, p. E54-E58 [How to Cite?]
DOI: http://dx.doi.org/10.1210/jc.2011-1930
AbstractAims: Fibroblast growth factor (FGF) 21 is an endocrine factor with multiple beneficial effects on glucose and lipid metabolism in animals. This study aimed to investigate the association of serum FGF21 levels with type 1 diabetes, latent autoimmune diabetes in adults (LADA) and type 2 diabetes. Methods: Serum FGF21 levels were determined by ELISA in patients with type 1 diabetes (n = 76), LADA (n = 68), type 2 diabetes (n = 77), and their age- and sex-matched controls. The association of serum FGF21 with markers of autoimmunity was studied. Results: In type 1 diabetic patients, serum FGF21 levels were significantly lower than controls [108.3 (61.5-180.1) vs. 196.0 (103.7-330.9) pg/ml, P < 0.001]. In LADA patients, serum FGF21 levels were significantly lower than controls after adjustment for body mass index [210.9 (121.4-441.6) vs. 268.3 (159.5-443.6) pg/ml, P = 0.003]. By contrast, serum FGF21 levels in type 2 diabetic patients were significantly higher than controls [381.2 (244.7-531.3) vs. 301.4 (173.9-444.2) pg/ml, P = 0.006]. FGF21 levels increased progressively from type 1 diabetes, LADA, to type 2 diabetes (P < 0.001 for global trend). Furthermore, FGF21 levels correlated inversely with titers of glutamic acid decarboxylase and insulinoma-associated protein 2 autoantibodies in type 1 diabetic and LADA patients. Conclusions: Serum FGF21 level is increased in type 2 diabetes but decreased in type 1 diabetes and LADA. In autoimmune diabetes, the reduction in circulating FGF21 is closely associated with markers of pancreatic β-cell autoimmunity. Copyright © 2012 by The Endocrine Society.
ISSN0021-972X
2011 Impact Factor: 5.967
2011 SCImago Journal Rankings: 0.579
DOIhttp://dx.doi.org/10.1210/jc.2011-1930
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorXiao, Y
dc.contributor.authorXu, A
dc.contributor.authorLaw, LSC
dc.contributor.authorChen, C
dc.contributor.authorLi, H
dc.contributor.authorLi, X
dc.contributor.authorYang, L
dc.contributor.authorLiu, S
dc.contributor.authorZhou, Z
dc.contributor.authorLam, KSL
dc.date.accessioned2012-09-05T05:32:39Z
dc.date.available2012-09-05T05:32:39Z
dc.date.issued2012
dc.description.abstractAims: Fibroblast growth factor (FGF) 21 is an endocrine factor with multiple beneficial effects on glucose and lipid metabolism in animals. This study aimed to investigate the association of serum FGF21 levels with type 1 diabetes, latent autoimmune diabetes in adults (LADA) and type 2 diabetes. Methods: Serum FGF21 levels were determined by ELISA in patients with type 1 diabetes (n = 76), LADA (n = 68), type 2 diabetes (n = 77), and their age- and sex-matched controls. The association of serum FGF21 with markers of autoimmunity was studied. Results: In type 1 diabetic patients, serum FGF21 levels were significantly lower than controls [108.3 (61.5-180.1) vs. 196.0 (103.7-330.9) pg/ml, P < 0.001]. In LADA patients, serum FGF21 levels were significantly lower than controls after adjustment for body mass index [210.9 (121.4-441.6) vs. 268.3 (159.5-443.6) pg/ml, P = 0.003]. By contrast, serum FGF21 levels in type 2 diabetic patients were significantly higher than controls [381.2 (244.7-531.3) vs. 301.4 (173.9-444.2) pg/ml, P = 0.006]. FGF21 levels increased progressively from type 1 diabetes, LADA, to type 2 diabetes (P < 0.001 for global trend). Furthermore, FGF21 levels correlated inversely with titers of glutamic acid decarboxylase and insulinoma-associated protein 2 autoantibodies in type 1 diabetic and LADA patients. Conclusions: Serum FGF21 level is increased in type 2 diabetes but decreased in type 1 diabetes and LADA. In autoimmune diabetes, the reduction in circulating FGF21 is closely associated with markers of pancreatic β-cell autoimmunity. Copyright © 2012 by The Endocrine Society.
dc.description.natureLink_to_OA_fulltext
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism, 2012, v. 97 n. 1, p. E54-E58 [How to Cite?]
DOI: http://dx.doi.org/10.1210/jc.2011-1930
dc.identifier.doihttp://dx.doi.org/10.1210/jc.2011-1930
dc.identifier.epageE58
dc.identifier.hkuros204675
dc.identifier.issn0021-972X
2011 Impact Factor: 5.967
2011 SCImago Journal Rankings: 0.579
dc.identifier.issue1
dc.identifier.pmid22013098
dc.identifier.scopuseid_2-s2.0-84862928486
dc.identifier.spageE54
dc.identifier.urihttp://hdl.handle.net/10722/163504
dc.identifier.volume97
dc.languageeng
dc.publisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
dc.publisher.placeUnited States
dc.relation.ispartofJournal of Clinical Endocrinology and Metabolism
dc.relation.referencesReferences in Scopus
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAutoimmunity - Physiology
dc.subject.meshBlood Glucose - Analysis
dc.subject.meshCase-Control Studies
dc.subject.meshChild
dc.subject.meshDiabetes Mellitus - Blood - Classification
dc.subject.meshDiabetes Mellitus, Type 1 - Blood
dc.subject.meshDiabetes Mellitus, Type 2 - Blood
dc.subject.meshFemale
dc.subject.meshFibroblast Growth Factors - Analysis - Blood
dc.subject.meshHumans
dc.subject.meshInsulin-Secreting Cells - Immunology
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.titleDistinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Central South University China